Trimble Navigation (TRMB)

$49.35 0.44 (0.88%)

17:56 EDT TRMB Stock Quote Delayed 30 Minutes

Volume:

Previous Close $49.35

Market Cap 12.30B

PE Ratio 96.76

EPS 0.51

Volume (Avg. Vol.) 1.98M

Day's Range 48.83 - 50.35

52-Week Range 20.01 - 54.51

Dividend & Yield N/A (N/A)

TRMB Stock Predictions, Articles, and Trimble Navigation News

From InvestorPlace
From the Web

10 Robotics Stocks on the Technological Cutting Edge

By Vince Martin, InvestorPlace Contributor Jun 18, 2020

Robotics stocks offer multi-decade growth potential. These 10 stocks offer some of the best exposure to this attractive trend.

3 Stocks to Watch on Tuesday: Citigroup Inc (C), Snap Inc (SNAP) and Trimble Inc (TRMB)

By Karl Utermohlen, InvestorPlace Writer May 8, 2018

Citigroup (C) shares rise on investing activity, Snap (SNAP) shares gain as company names Tim Stone as CFO and Trimble (TRMB) tops analysts' earnings projections.

Lifestyle Drugs Market 2020 Analysis and Precise Outlook – Allergan, BMS, Eli Lilly, Pfizer, Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience

From X herald Sep 19, 2020

Continue reading "Lifestyle Drugs Market 2020 Analysis and Precise Outlook – Allergan, BMS, Eli Lilly, Pfizer, Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience"

Moderna and Pfizer set different efficacy bars in pivotal COVID-19 trials (NASDAQ:MRNA)

From Seeking Alpha Sep 19, 2020

Amid concerns among Americans that the rush to approve COVID-19 vaccines may lead to corner-cutting and end products that are not up to typical FDA efficacy standards, leading developers Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) have taken the unusual steps of publishing the protocols of the large-scale late-stage trials for their respective candidates.Moderna's Phase 3 trial of mRNA-1273, two 100 microgram doses 28 days apart, will recruit ~30K adults, 60-75% younger than 65 years old not at risk for complications and 25-40% at least 65 years old (the single most significant risk factor) or less than 65 at increased risk of COVID-19 complications.The primary efficacy endpoint is the incidence of first-occurrence COVID-19 cases starting 14 days after the second shot.A confirmed (via molecular test) COVID-19 case is defined as a participant who has experienced at least TWO of the following symptoms: fever (≥ 38ºC), chills, myalgia (muscle soreness), headache, sore throat, new olfactory and taste disorder(s) OR he/she must have experienced at least ONE of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing OR clinical or radiographic evidence of pneumonia.Pfizer and BioNTech's (NASDAQ:BNTX) Phase 3 study of BNT162b2, two 30 microgram doses 21 days apart, will recruit 30K adults stratified in two groups: 16-55 years old and 55+.The primary efficacy endpoint is the incidence of confirmed COVID-19 cases starting 7 days after the second shot as measured by the number of cases per 1,000 person-years of follow-up.A confirmed (via molecular test) COVID-19 case is defined as participants experiencing at least ONE of the following symptoms: fever, new or increased cough, new or increased shortness of breath, chills, new or increased myalgia (muscle soreness), new loss of taste or smell, sore throat, diarrhea or vomiting.Moderna's criteria are a more restrictive and could potentially show a higher efficacy rate for mRNA-1273 as a result.The number of COVID-19 cases in people who just reported one symptom is unknown.

Business Chiefs Push Cuomo, de Blasio to Bolster NYC After Covid

From Bloomberg Sep 18, 2020

New York business leaders are pushing Governor Andrew Cuomo and Mayor Bill de Blasio to consider ways of ensuring that the nation’s biggest city retains its economic dominance in the wake of the coronavirus pandemic.

Epilepsy Drugs Market to See Huge Growth by 2026 : UCB Pharma, Pfizer, GlaxoSmithKline

From SBWire Sep 18, 2020

Stay up-to-date with Epilepsy Drugs Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.

Acute Coronary Syndrome Therapeutic Market Research Report by Type, by Drug, by Treatment, by Diagnosis, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19

From BusinessInsider Sep 18, 2020

New York, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report 'Acute Coronary Syndrome Therapeutic Market Re...

Unusual Options Activity Insight: Pfizer

From Benzinga Sep 18, 2020

On Friday, shares of Pfizer (NYSE: PFE) saw unusual options activity. After the option alert, the stock price moved down to $36.69. Sentiment: BULLISH Option Type: SWEEP Trade...

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy